Kumar Abhishek, Paramasivam Nagarajan, Bandapalli Obul Reddy, Schlesner Matthias, Chen Tianhui, Sijmons Rolf, Dymerska Dagmara, Golebiewska Katarzyna, Kuswik Magdalena, Lubinski Jan, Hemminki Kari, Försti Asta
Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, D-69120, Heidelberg, Germany.
Institute of Bioinformatics, International Technology Park, Bangalore, 560066, India.
Hered Cancer Clin Pract. 2021 Jan 19;19(1):10. doi: 10.1186/s13053-021-00167-0.
The most frequently identified strong cancer predisposition mutations for colorectal cancer (CRC) are those in the mismatch repair (MMR) genes in Lynch syndrome. Laboratory diagnostics include testing tumors for immunohistochemical staining (IHC) of the Lynch syndrome-associated DNA MMR proteins and/or for microsatellite instability (MSI) followed by sequencing or other techniques, such as denaturing high performance liquid chromatography (DHPLC), to identify the mutation.
In an ongoing project focusing on finding Mendelian cancer syndromes we applied whole-exome/whole-genome sequencing (WES/WGS) to 19 CRC families.
Three families were identified with a pathogenic/likely pathogenic germline variant in a MMR gene that had previously tested negative in DHPLC gene variant screening. All families had a history of CRC in several family members across multiple generations. Tumor analysis showed loss of the MMR protein IHC staining corresponding to the mutated genes, as well as MSI. In family A, a structural variant, a duplication of exons 4 to 13, was identified in MLH1. The duplication was predicted to lead to a frameshift at amino acid 520 and a premature stop codon at amino acid 539. In family B, a 1 base pair deletion was found in MLH1, resulting in a frameshift and a stop codon at amino acid 491. In family C, we identified a splice site variant in MSH2, which was predicted to lead loss of a splice donor site.
We identified altogether three pathogenic/likely pathogenic variants in the MMR genes in three of the 19 sequenced families. The MLH1 variants, a duplication of exons 4 to 13 and a frameshift variant, were novel, based on the InSiGHT and ClinVar databases; the MSH2 splice site variant was reported by a single submitter in ClinVar. As a variant class, duplications have rarely been reported in the MMR gene literature, particularly those covering several exons.
在林奇综合征中,结直肠癌(CRC)最常被鉴定出的强癌症易感性突变是错配修复(MMR)基因中的突变。实验室诊断包括检测肿瘤的林奇综合征相关DNA错配修复蛋白的免疫组织化学染色(IHC)和/或微卫星不稳定性(MSI),随后进行测序或其他技术,如变性高效液相色谱(DHPLC),以鉴定突变。
在一个正在进行的专注于发现孟德尔癌症综合征的项目中,我们对19个CRC家族应用了全外显子组/全基因组测序(WES/WGS)。
在3个家族中鉴定出在MMR基因中有一个致病/可能致病的种系变异,这些家族在之前的DHPLC基因变异筛查中检测为阴性。所有家族在多代的多个家族成员中都有CRC病史。肿瘤分析显示与突变基因相对应的MMR蛋白IHC染色缺失以及MSI。在家族A中,在MLH1中鉴定出一个结构变异,即外显子4至13的重复。该重复预计会导致第520位氨基酸处的移码和第539位氨基酸处的提前终止密码子。在家族B中,在MLH1中发现了1个碱基对的缺失,导致移码并在第491位氨基酸处出现终止密码子。在家族C中,我们在MSH2中鉴定出一个剪接位点变异,预计会导致一个剪接供体位点的缺失。
在19个测序家族中的3个家族中,我们总共在MMR基因中鉴定出3个致病/可能致病的变异。基于InSiGHT和ClinVar数据库,MLH1变异,即外显子4至13的重复和一个移码变异,是新发现的;MSH2剪接位点变异在ClinVar中仅有一位提交者报告过。作为一种变异类型,重复在MMR基因文献中很少被报道,尤其是那些覆盖多个外显子的重复。